Patients With Moderate-to-Severe Atopic Dermatitis Maintained Depth of Response Up to 2 Years With Continuous Abrocitinib Treatment. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Apr. 29];9(6):s617. Available from: https://skin.dermsquared.com/skin/article/view/3821